EUCTR2021-000364-30-Outside-EU/EEA进行中（未招募）1 期
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Part A: participants with recurrent or refractory non-CNS solid tumors
- •-Part B: participants with recurrent or refractory CNS tumors
- •-Measurable or evaluable disease
- •-No other therapeutic options
- •-Performance Status: Karnofsky =50% for participants >16 years and Lansky =50 for participants =16 years
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 30
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •-Active or recent history of serious bleeding events
- •-Active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
- •-Active or recent history of hypertensive crisis or hypertensive encephalopathy
- •-Active non-healing wound or bone fracture
- •-History of solid organ transplant
研究者
相似试验
已完成
1 期
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid TumorsPediatric Solid TumorRefractory TumorRecurrent TumorCNS MalignanciesNCT02564198Eli Lilly and Company29
进行中（未招募）
1 期
A sing le-arm, phase I study of ramucirumab in combination with erlotinib or osimertinib in previously untreated patients with EGFR mutantion-posit ive metastatic Non-small cell lung cancer with brain metastaseslung carcinoma, non small cellD002289JPRN-jRCT2051190027Kaneda Hiroyasu6
未知
1 期
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaStomach NeoplasmsJPRN-jRCT2080222764Eli Lilly Japan K.K.
进行中（未招募）
1 期
A Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Lung Cancer Following Disease Progression after Prior Platinum-based ChemotherapyStage IV non-small cell lung cancer (NSCLC)MedDRA version: 19.0Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864EUCTR2016-001317-25-ESilly S.A.50
进行中（未招募）
1 期
A Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Lung Cancer Following Disease Progression after Prior Platinum-based ChemotherapyEUCTR2016-001317-25-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER50